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The G-protein-coupled receptors (GPCRs) family of proteins play essential roles in the heart, including in
the regulation of cardiac hypertrophy. One member of this family, the oxoglutarate receptor 1 (OXGR1),
may have a crucial role in the heart because it acts as a receptor for a-ketoglutarate, a metabolite that is
elevated in heart failure patients. OXGR1 is expressed in the heart but its precise function during cardiac
pathophysiological process is unknown. Here we used both in vivo and in vitro approaches to investigate
the role of OXGR1 in cardiac hypertrophy.
Genetic ablation of Oxgr1 in mice (OXGR1/) resulted in a signiﬁcant increase in hypertrophy
following transverse aortic constriction (TAC). This was accompanied by reduction in contractile function
as indicated by cardiac fractional shortening and ejection fraction. Conversely, adenoviral mediated
overexpression of OXGR1 in neonatal rat cardiomyocytes signiﬁcantly reduced phenylephrine-induced
cardiomyocyte hypertrophy, a result that was consistent with the in vivo data. Using a combination of
yeast two hybrid screening and phospho-antibody array analysis we identiﬁed novel interacting partner
and downstream signalling pathway that might be regulated by the OXGR1. First, we found that OXGR1
forms a molecular complex with the COP9 signalosome complex subunit 5 (CSN5). Secondly, we
observed that the STAT3 signalling pathway was upregulated in OXGR1/ hearts. Since CSN5 interacts
with TYK2, a major upstream regulator of STAT3, OXGR1 might regulate the pro-hypertrophic STAT3
pathway via interaction with the CSN5-TYK2 complex.
In conclusion, our study has identiﬁed OXGR1 as a novel regulator of pathological hypertrophy via the
regulation of the STAT3. Identiﬁcation of molecules that can speciﬁcally activate or inhibit this receptor
may be very useful in the development of novel therapeutic approach for pathological cardiac
hypertrophy.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The global burden of heart failure (HF) is increasing, with the
projection that HF prevalence will increase signiﬁcantly in the next
decade [1]. Left ventricular hypertrophy is independently associ-
ated with the incidence of HF [2]. It is an adaptive response to
pathological stimuli such as pressure and volume overload, or to
loss of myocytes following myocardial infarction. If left untreated
this response may eventually become maladaptive and progress tong, Oxford Road, Manchester,
(D. Oceandy).
r Inc. This is an open access articlheart failure [3]. In terms of regulatory mechanisms a number of
molecular signalling pathways have been implicated in the devel-
opment of cardiac hypertrophy [4]. Many of these signalling path-
ways are controlled and modulated by membrane receptors, which
sense signals from the outside of cells and transmit them to the
intracellular effectors. One of themajor membrane receptor protein
families that plays a key role in the heart is the G protein-coupled
receptor family (GPCRs).
It has long been appreciated that the GPCRs regulate a large
number of essential processes in the heart including cardiac
contractility and hypertrophy. Upon activation the GPCRs may
induce the G protein-dependent and the G protein-independent
pathways (reviewed in Ref. [5]). The G protein-dependent
pathway involves activation of the heterotrimeric G proteine under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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as cAMP, cGMP and di-acyl glycerol (DAG). The G protein-
independent pathway is initiated by phosphorylation of the re-
ceptor by the GPCR kinases (GRKs), triggering the binding and
activation of the b-arrestin signalosomes [5]. Because GPCRs are
located on the plasma membrane they are relatively amenable to
pharmacological targeting for therapeutic purposes. For example,
b-adrenergic receptor blockers and angiotensin II receptor blockers
target GPCRs and have been widely used to control blood pressure
and inhibit hypertrophic signalling [6,7].
Human and mouse genome sequence analysis has predicted
that there are more than 400 non-olfactory GPCRs [8]; however
many of their functions are not known. In this study we examined
the functional role of oxoglutarate receptor 1 or OXGR1 (also
known as GPR80 or GPR99) in the heart. OXGR1 was ﬁrst regarded
as an orphan receptor, but He and colleagues have identiﬁed it as a
receptor for a-ketoglutarate, a citric acid cycle (CAC) intermediate
[9]. Importantly, recent advances in the cardiac metabolomics ﬁeld
have recognized that CAC intermediates may play crucial roles in
several cardiac diseases. For example succinate, which is markedly
elevated following myocardial ischemic injury [10], may also pro-
duce biological effects by controlling reactive oxygen species pro-
duction [11]. Other evidence of particular relevance to this study,
showed that a-ketoglutarate is signiﬁcantly elevated in the serum
of patients with HF [12]. Therefore, it is important to understand
the role of the OXGR1 receptor in the heart, particularly in patho-
logical conditions. Using a mouse model with genetic ablation of
the Oxgr1 gene, in this study we investigated the role of OXGR1
during pressure overload-induced cardiac hypertrophy.
2. Materials and methods
2.1. Animal model
The OXGR1 knockout (OXGR1/) mice were obtained from the
Knockout Mouse Project (KOMP) repository. They were generated
by targeting the exon 4 of the Oxgr1 gene. The in vivo hypertrophy
experiments were carried out on 8e10 week old male mice. We
used age and sex matched wild type (WT) littermates as control.
The OXGR1/ mice were maintained on a C57Bl/6 genetic back-




which will produce WT allele fragment of 556 bp and KO allele
fragment of 392 bp.
In vivo studies were performed in accordance with the United
Kingdom Animals (Scientiﬁc Procedures) Act 1986 and were
approved by the University of Manchester Ethics Committee.
2.2. Pressure overload hypertrophy model
To induce cardiac pressure overload, mice were subjected to
transverse aortic constriction (TAC) using a procedure described
previously [13]. In brief, the aortic arch was ligated on a 27-gauge
needle using 7-0 silk suture. Then the needle was released
causing a constriction of the aorta which would produce a
~25e30mmHg pressure gradient between the right and left carotid
artery.
2.3. Echocardiography analysis
Transthoracic echocardiography was performed following aprotocol described previously [14]. Brieﬂy,micewere anaesthetized
with 1.5% isoﬂuorane, then the two-dimensional short-axis view as
well as M-mode echocardiography were recorded. Cardiac wall
thickness, chamber dimension, fractional shortening and ejection
fraction were determined from these imaging techniques.
2.4. Histology analysis
Mouse heart tissues were ﬁxed in phosphate-buffered saline
(PBS) containing 4% paraformaldehyde. They were embedded in
parafﬁn and then sectioned at 5 mm thickness. Hematoxylin& eosin
staining was performed for the measurement of cross-sectional
cardiomyocyte size. We used ImageJ software (NIH) for
measuring cross-sectional cell size and ﬁbrotic area.
2.5. Adenovirus generation
Plasmid containing human OXGR1 cDNA was obtained from
Origene. The ORF fragment was cloned to pENTR-11 (Invitrogen)
and then transferred to the adenovirus vector pAd-CMV-DEST
(Invitrogen) by using the Gateway vector system (Invitrogen) to
produce the pAd-CMV-OXGR1. Adenovirus was generated by
transfecting the pAd-CMV-OXGR1 to HEK293 cells.
2.6. Cellular hypertrophy experiments
Neonatal rat cardiomyocytes (NRCM) were used for the cellular
hypertrophy experiments. NRCM were isolated from 1 to 3 day old
Sprague-Dawley rat neonates using methods described previously
[13]. Isolated NRCM were maintained in medium containing 80%
DMEM and 20% Medium 199, 1% FBS, 2.5 mg per ml amphotericin B
and 1 mM BrdU. To induce hypertrophy, NRCM infected with Ad-
OXGR1 or Ad-LacZ (control) were treated with 30 mM phenyleph-
rine for 72 h. Cells were then stained with anti-a-actinin antibody
(Sigma) and the size was measured using ImageJ software.
2.7. Yeast two-hybrid screen
A DNA fragment of the human OXGR1 gene, which encodes
amino acids 306 to 337 corresponding to the C-terminus intracel-
lular domain of OXGR1, was cloned into the pGBT9 DNA-BD
downstream of the GAL4 DNA binding domain. This construct
was then used as bait in a yeast two-hybrid screen analysis against
the universal human cDNA library. The yeast two-hybrid screening
service was provided by the Genomics and Proteomics Core Facil-
ities, Protein Interaction Screening - German Cancer Research
Center (DKFZ), Heidelberg, Germany.
2.8. Western blot
Proteins from mouse heart tissues or from cultured NRCM were
extracted using RIPA buffer (PBS containing 1% IGEPAL CA-630, 0.5%
sodium deoxycholate, 0.1% SDS, 0.5 mM PMSF, 500 ng per ml
Leupeptin, 1 mg per ml Aprotinin, 2.5 mg per ml Pepstatin A).
Western blot analysis was performed using a protocol described
previously [14]. Primary antibodies used were: anti-OXGR1, anti-
pSTAT3, anti-STAT3, anti-CSN5, anti-GAPDH (all from Abcam), anti-
TYK2 (Santa Cruz Biotechnology) and anti-a-actinin (Sigma). The
HRP-conjugated secondary antibodies were from Cell Signaling
Technologies. We used the PathScan Intracellular Signaling Array
kit (Cell Signaling) for the antibody array analysis.
2.9. Immunoprecipitation
Protein extracts were pre-cleared by incubation with Protein G/
A. Omede et al. / Biochemical and Biophysical Research Communications 479 (2016) 708e714710A agarose (Calbiochem/Merck Millipore) for 2 h at room tempera-
ture. Pre-cleared extracts were then incubated overnight with 5 mg
of indicated antibody and 20 ml of Protein G/A agarose. Beads were
washed three times with 500 ml RIPA buffer and then resuspended
in Laemmli loading buffer for analysis by Western blot.
2.10. Statistical analysis
Data are expressed as mean ± SEM. Student's t-test or one way
ANOVA followed by post-hoc multiple comparison were used
where appropriate. The probability level for statistical signiﬁcance
was set at p < 0.05.
3. Results
3.1. OXGR1 ablation enhanced pressure overload hypertrophy in
mice
We analysed mice with systemic genetic ablation of the
Oxgr1gene. Western blot analysis to examine the expression of
OXGR1 in the heart showed that OXGR1 was expressed in WT
hearts but was almost completely ablated in the OXGR1/ mice
(Fig. 1A). Basally, the knockout mice appeared grossly normal with
no apparent changes in cardiac size and function (data not shown).
To investigate the effect of OXGR1 ablation under pathological
conditions, we then performed transverse aortic constriction (TAC)
to induce cardiac hypertrophy. We found that OXGR1/ mice
exhibited a greater hypertrophic response as shown in Fig. 1BeC.
Measurement of heart weight/body weight ratio (HW/BW)
conﬁrmed a signiﬁcant increase in cardiac size in the OXGR1/Fig. 1. OXGR1/mice exhibit an elevated level of hypertrophic response to pressure overloa
OXGR1/mice. B) Representative images of hearts from OXGR1/ and WT mice subjected
HW/BW ratio showed signiﬁcant increase in hypertrophic response in OXGR1/ mice (n ¼
hematoxylin-eosin and (E) quantiﬁcation of cardiomyocyte cross sectional area showed la
Expression of hypertrophic marker ANP was detected using real time qPCR (n ¼ 4e7 in eamice comparedwith wild type (WT) littermates (Fig. 1C). To further
characterize the hypertrophic response we examined car-
diomyocyte cross sectional size from histological sections. Consis-
tently, OXGR1/mice displayed signiﬁcantly larger cardiomyocyte
cross sectional area after TAC compared with WT littermates (WT
TAC, 460.2 ± 6.8 mm2, KO TAC, 549.6 ± 6.7 mm2) (Fig. 1DeE). In
consistent with these ﬁndings, expression of hypertrophic marker
Atrial Natriuretic Peptide (ANP) was signiﬁcantly elevated in
OXGR1/ TAC compared to WT TAC group (Fig. 1F). Overall, our
observations suggested that OXGR1might play an important role in
the development of pressure overload hypertrophy, in which its
ablation exaggerated the hypertrophic growth of the heart.
3.2. Echocardiography analysis
We assessed echocardiography parameters and observed that
the OXGR1/ mice following TAC displayed increased cardiac
posterior wall thickness (Fig. 2A) although the septal wall thickness
was not signiﬁcantly different (Fig. 2B). Whenwe examined cardiac
contractility we found that the cardiac fractional shortening and
ejection fraction of the OXGR1/ TAC group were signiﬁcantly less
than those of theWT TAC group (Fig. 2CeD), indicating a signiﬁcant
reduction of cardiac contractile function in the OXGR1/mice after
TAC.
3.3. OXGR1 overexpression in cardiomyocytes reduced the
hypertrophic response
To analyse the effects of OXGR1 gain of function, we generated
an in vitro model of OXGR1overexpression by producing and. A)Western blot analysis shows that expression of OXGR1 was ablated in the hearts of
to either transverse aortic constriction (TAC) for 2 weeks or sham surgery. C) Analysis of
6e10 in each group; *P < 0.05). D) Representative histological sections stained with
rger cardiomyocyte size in OXGR1/ mice after TAC (scale bars 50 mm,*P < 0.05). F)
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Fig. 2. Echocardiography analyses of cardiac morphology and function. A) LV posterior wall thickness was signiﬁcantly thicker in OXGR1/ mice compared to WT after TAC
(n ¼ 5e6; *P < 0.05), however there was no signiﬁcant difference in septal wall thickness between OXGR1/ TAC vs WT TAC group (B). C) Following TAC OXGR1/ mice displayed
signiﬁcantly lower cardiac contractile function as indicated by fractional shortening and (D) Ejection fraction compared to WT controls (n ¼ 5e6; *P < 0.05).
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duce neonatal rat cardiomyocytes (NRCM) and to induce OXGR1
overexpression (Fig. 3A). We used this model to evaluate the effect
of OXGR1 overexpression in a cellular model of hypertrophy. NRCM
were treated with either adenovirus expressing OXGR1 (Ad-
OXGR1) or a control virus (Ad-LacZ). We then exposed NRCM to
30 mM phenylephrine (PE) for 72 h to induce cellular hypertrophy
(Fig. 3B). We found that OXGR1 overexpression markedly reduced
the phenylephrine-induced hypertrophy as indicated by cell sur-
face area measurement (Fig. 3C). This data is in agreement with the
in vivo results showing that OXGR1 overexpression inhibited the
development of hypertrophy.3.4. OXGR1 interacts with COP9 Constitutive Photomorphogenic
Homolog Subunit 5 (CSN5/JAB1/COPS5)
As a ﬁrst step to characterize the signalling pathways that are
regulated by OXGR1, we performed experiments to identify pro-
teins that interact with this receptor. We conducted yeast two-
hybrid screen analysis to identify potential interacting partners of
OXGR1. We used the cytoplasmic carboxy-terminus region of
OXGR1 as a bait, since this is the largest cytoplasmic domain of this
molecule. We cloned human OXGR1 cDNA encoding amino acids
306e337 into a plasmid to generate a hybrid protein containing a
GAL4-DNA binding domain and the OXGR1306337 fragment
(Fig. 3D). The yeast two-hybrid screen was performed against a
human universal cDNA library. Sequence analysis of the positive
clones showed that most of the prey fragments identiﬁed were 30
UTR sequences; however, there was one fragment identiﬁed that
corresponded to the coding sequence of the COP9 Constitutive
Photomorphogenic Homolog Subunit 5 (COPS5) gene, which is also
known as CSN5 or JAB1 (Table 1).
CSN5 is a signalling molecule involved in various cellularprocesses. It was described as a component of the COP9 signal-
osome, which is important in the regulation of kinase signalling
and ubiquitin-dependent protein degradation [15]. CSN5 may also
function independent of the COP9 complex by interacting with
other molecules [16]. To further conﬁrm if CSN5 forms a complex
with OXGR1 we conducted immunoprecipitation analysis. As
shown in Fig. 4a we demonstrated co-precipitation of OXGR1 and
CSN5 in isolated cardiomyocytes, suggesting protein interaction
between OXGR1-CSN5. Next, we analysed CSN5 expression in the
heart of WT and OXGR1/ mice at basal conditions and after TAC
stimulation. We found that there was no difference in basal CSN5
expression between WT and OXGR1/ mice. Cardiac CSN5 level
was signiﬁcantly increased following TAC stimulation; however,
expression in OXGR1/mice following TACwas signiﬁcantly lower
than in WT TAC mice (Fig. 4BeC). This data indicated the possible
involvement of CSN5 in the signal regulation downstream of
OXGR1 during pressure overload cardiac hypertrophy.3.5. STAT3 is highly activated in OXGR1/ mice
To further investigate the downstream effectors of OXGR1 we
used a phospho-kinase antibody array to seek kinases that are
differentially phosphorylated in OXGR1/ mice after TAC. Using
this approach we identiﬁed several highly phosphorylated kinases
in the knockout mice including STAT3 (Fig. 4D). Importantly, STAT3
signalling has been associated with the regulation of cardiac hy-
pertrophy with reports suggesting that overactivation of STAT3
might result in an overt hypertrophic response [17]. We then per-
formed Western blot analysis to conﬁrm this ﬁnding. As shown in
Fig. 4eeF we detected signiﬁcantly higher phosphorylation levels of
STAT3 in OXGR1/ TAC mice compared to the WT TAC group.
STAT3 is activated by a number of molecules, including janus kinase
(JAK) and tyrosine kinase 2 (TYK2) [18]. In particular TYK2 may be
Fig. 3. OXGR1 overexpression in cardiomyocytes inhibited phenylephrine-induced hypertrophy. A) Western blot analysis showing expression of OXGR1 in neonatal rat car-
diomyocytes (NRCM) following infection with adenovirus expressing human OXGR1 (Ad-OXGR1). Adenovirus expressing LacZ (Ad-LacZ) was used as a control. B) Representative
images of NRCM overexpressing OXGR1 and control (LacZ) following treatment with 30 mM phenylephrine (PE) for 72 h. NRCM were stained with anti a-actinin antibody to
speciﬁcally visualise cardiomyocytes. Scale bars 100 mm. C) Measurement of cell surface area indicated that OXGR1 overexpression signiﬁcantly reduced PE-induced hypertrophy
(*P < 0.05). D) Schematic diagram of the GAL4-DBD-OXGR1306337 recombinant protein used as a bait in the yeast two hybrid screening.
Table 1
List of positive clones obtained from the yeast two hybrid screen using GAL4-
OXGR1306337 as a bait.
Gene symbol Fluorescent signal (fold induction) Location of prey fragment
NEUROD2 2.97 30 UTR
ZAK 2.27 30 UTR
RDX 2.11 30 UTR
CSN5 2.10 ORF
RETSAT 1.93 30 UTR
CHTOP 1.83 30 UTR
IBTK 1.75 30 UTR
LRRC59 1.52 30 UTR
KCNMA1 1.48 30 UTR
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protein complex since recent reports have suggested that TYK2
interacts with CSN5 [19].
To test the hypothesis that TYK2 is involved in OXGR1 mediated
signalling we performed immunoprecipitation analysis in isolated
cardiomyocytes. As shown in Fig. 4g TYK2 co-precipitated with
CSN5 indicating a possible physical interaction between these
molecules. Taken together, the data indicated that OXGR1 might
regulate the pro-hypertrophic STAT3 signal through modulation of
CSN5 and TYK2.4. Discussion
In this study we identify OXGR1 as a regulator of pathological
cardiac hypertrophy. Loss of OXGR1 expression resulted in
enhanced cardiac hypertrophy and marked reduction of contractile
function following pressure overload stimulus. OXGR1 may control
cardiac hypertrophic growth by suppressing STAT3 activation via itsinteraction with CSN5 and TYK2.
OXGR1 is a member of the G protein coupled receptor super
family of proteins. It was ﬁrst regarded as a member of the P2Y
family of nucleotide receptors (P2Y) based on sequence homology
and its ability to respond to adenosine or AMP stimulation [20]. A
reports by He et al. however, has identiﬁed OXGR1 as a ligand for
the citric acid cycle intermediate a-ketoglutarate [9], hence OXGR1
is now regarded as a receptor for citric acid cycle intermediates.
More recently, OXGR1 has also been described as a receptor for
cysteinyl leukotriene in particular leukotriene E4 [21]. This ﬁnding
has added more possible physiological functions for OXGR1.
Here we demonstrated that OXGR1 expression during pressure-
overload hypertrophy might be essential since in mice with com-
plete loss of OXGR1 the extent of cardiac hypertrophy was
augmented after 2 weeks of TAC. It was logical to speculate that
OXGR1 acted as a suppressor of cardiac hypertrophy and results
from the in vitro studies using an adenoviral-mediated OXGR1
overexpression system supported this notion; however, it is also
important to know whether OXGR1 regulates the maladaptive or
the adaptive hypertrophic pathways. Echocardiography analysis
suggested a signiﬁcant reduction of cardiac contractility and
increased remodelling, indicating a possible increase in maladap-
tive response in the knockout mice.
We have identiﬁed CSN5, also known as JAB1, as an interacting
partner of OXGR1 by yeast two-hybrid screen, which was
conﬁrmed by immunoprecipitation analysis. CSN5 is known as a
regulator of several important cellular processes such as protein
phosphorylation, ubiquitination and nuclear-cytoplasmic trans-
location [22]. It exerts its cellular function via its presence as a
single molecule or as part of the COP9 signalosome complex [22]. In
the heart CSN5 has been implicated in modulation of L-type Ca
channel activity [23]; however, its role in mediating cardiac
Fig. 4. OXGR1 regulates STAT3 activation possibly by interaction with CSN5 and TYK2. A) Immunoprecipitation analysis of mouse heart extracts showed that OXGR1 was co-
precipitated with CSN5 suggesting a possible physical interaction between these molecules. B) Western blot of CSN5 level in the heart and C) Quantiﬁcation of CSN5 band den-
sity normalised to GAPDH level indicated that CSN5 expression was signiﬁcantly reduced in OXGR1/ TAC group compared to WT TAC group (*P < 0.05). D) Images from phospho-
kinase antibody array analysis showing that STAT3 phosphorylation might be increased in OXGR1/ TAC mice. E) Western blot analysis phosphorylated and total STAT3 and F)
Measurement of band density conﬁrmed that STAT3 phosphorylation level was signiﬁcantly increased in the OXGR1/ TAC group compared to WT-TAC (*P < 0.05). G) Immu-
noprecipitation with TYK2 antibody suggested that TYK2 might form interaction with CSN5 in the heart. H) Schematic diagram of possible signaling pathway regulated by OXGR1 in
the heart. OXGR1 may negatively regulate TYK2-STAT3 pathway via CSN5.
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We therefore used an antibody array system to probe possible
downstream signalling pathways regulated by the OXGR1-CSN5
complex. We found that STAT3 activation was upregulated in
OXGR1/mice. This prompted us to hypothesize that STAT3 might
be the downstream pathway regulated by the OXGR1-CSN5 com-
plex. It is known that STAT3 phosphorylation can be mediated by
many factors [18] but one molecule that is required for STAT3
activation and may be relevant with the OXGR1-CSN5 complex is
TYK2. STAT3 is mainly activated by the gp130 receptor system
which requires the assembly of JAK and TYK-2 in the intracellular
domain of the gp130 receptor [18]. The formation of the gp130
receptor-JAK-TYK2 complex is essential for the docking of STAT3 in
the receptor complex and subsequent STAT3 phosphorylation.
Active TYK2 is required inmediating this process [24]. Interestingly,
Muromoto and colleagues have recently reported that TYK2 in-
teracts with CSN5 in HeLa cells [19]. Because we also found an
interaction between CSN5-TYK2 in cardiomyocytes, we reasoned
that CSN5 may regulate TYK2 activation and hence STAT3 phos-
phorylation in the heart. We show here that CSN5 expression is
induced by TAC and this effect is ablated in OXGR1/ mice.
However, STAT3 phosphorylation was more profound in the
OXGR1/ mice. This data suggests that the OXGR1-CSN5 complex
may act as a negative modulator of TYK2-STAT3 activation
following hypertrophic stimulus in the heart. We speculate that
OXGR1-CSN5 may act as negative regulator of STAT3 activation by
binding to TYK2 and preventing overt activation of the STAT3
pathway in the setting of pressure overload/mechanical stretch
(Fig. 4H). Thus, loss of OXGR1 will result in STAT3 being overly
phosphorylated and hence more profound hypertrophy.
In conclusion, our data has identiﬁed OXGR1 as a novel modu-
lator of pressure overload-induced cardiac hypertrophy. It remains
to be studied whether activation or inhibition of this receptor by itsligands/inhibitor will affect myocardial growth and remodelling;
however, the nature that OXGR1 is a membrane situated receptor
makes it highly amenable as a novel therapeutic target in the
future.
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